HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Executive Decisions: HPCUS Service Award For Land; Supplement VP New At CHPA; ACI Adds Microbiology Director; ABC Awards; More

Executive Summary

Mark Land receives HPCUS “Service to Homeopathy Award”; CHPA appoints John Troup to new post of dietary supplements executive; P&G’s Paul Gama elected CHPA board chair; FDA fellow, microbiology expert Queen joins ACI; more executive hires in consumer health and beauty sectors.

You may also be interested in...



CHPA Rebranding Reflects Growing Device Interests In Evolving Self-Care Market

The Consumer Healthcare Products Association’s rebranding initiative – its first in 20 years – aligns the group with today’s self-care marketplace where consumer medical devices play an increasingly prominent role. It also follows “landmark legislative achievements in 2020 that will further empower consumers to practice responsible self-care,” CHPA says.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel